It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
TNBC is a heterogeneous subtype of breast cancer, and only a subset of TNBC can be established as PDXs. Here, we show that there is an engraftment bias toward TNBC with low levels of immune cell infiltration. Additionally, TNBC that failed to engraft show gene expression consistent with a cancer-promoting immunological state, leading us to hypothesize that the immunological state of the tumor and possibly the state of the immune system of the host may be essential for engraftment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
2 Baylor College of Medicine, Lester and Sue Smith Breast Center, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
3 University of Utah, Eccles Institute of Human Genetics, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096); University of Utah, Huntsman Cancer Institute, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
4 University of Utah, Huntsman Cancer Institute, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096); University of Utah, Department of Oncological Sciences, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
5 University of Utah, Huntsman Cancer Institute, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096); University of Utah, Department of Surgery, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
6 Baylor College of Medicine, Lester and Sue Smith Breast Center, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Departments of Molecular and Cellular Biology and Radiology, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)